Tanja D de Gruijl

17PUBLICATIONS
61CO-AUTHORS
Predictive and prognostic markersMicro-manipulationCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|May 07, 2026
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.

|Oct 07, 2024
Environmentally Controlled Microfluidic System Enabling Immune Cell Flow and Activation in an Endothelialised Skin-On-Chip.

Elisabetta Michielon, Matteo Boninsegna, Taco Waaijman

|Jul 22, 2024
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven

|May 25, 2024
Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells.

Aram M de Haas, Dorian A Stolk, Sjoerd T T Schetters

|Jun 27, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.

Lisa A King, Elisa C Toffoli, Myrthe Veth

|Jun 22, 2023
A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion.

Elisabetta Michielon, Marta López González, Dorian A Stolk

Pageof 3

Frequent Collaborators

3 joint publications

Bas D Koster

3 joint publications

Alfons J M van den Eertwegh

3 joint publications

Elisabetta Michielon

3 joint publications

Susan Gibbs